Abstract
Global rates of pulmonary tuberculosis (TB) continue to increase. Moreover, resistance of the causative organism Mycobacterium tuberculosis to the two most effective anti-TB medications continue to rise. Now, multi-drug resistant TB (MDR-TB) has progressed to extensively drug resistant TB (XDR-TB) - a M. tuberculosis organism that is resistant to the most effective second line drugs available for the treatment of TB. This review provides detailed, significant evidence that supports the use of an old neuroleptic compound, thioridazine (TZ), for the management of MDR-TB and XDR-TB infections and which has been shown to inhibit efflux pumps of bacteria. The argument has been previously presented but no one seems to be listening - and the disease continues unabated when there is a very good probability that the suggested drug will prove to be effective. When the prognosis is poor, available therapy predictably ineffective and death is inevitable, compassionate therapy with TZ should be contemplated. The risks are small and the rewards great.
Keywords: Therapy of MDR-TB, XDR-TB, Mycobacterium tuberculosis, thioridazine, efflux pumps
Current Drug Targets
Title: Promising Therapy of XDR-TB/MDR-TB with Thioridazine an Inhibitor of Bacterial Efflux Pumps
Volume: 9 Issue: 9
Author(s): L. Amaral, M. Martins, M. Viveiros, J. Molnar and J. E. Kristiansen
Affiliation:
Keywords: Therapy of MDR-TB, XDR-TB, Mycobacterium tuberculosis, thioridazine, efflux pumps
Abstract: Global rates of pulmonary tuberculosis (TB) continue to increase. Moreover, resistance of the causative organism Mycobacterium tuberculosis to the two most effective anti-TB medications continue to rise. Now, multi-drug resistant TB (MDR-TB) has progressed to extensively drug resistant TB (XDR-TB) - a M. tuberculosis organism that is resistant to the most effective second line drugs available for the treatment of TB. This review provides detailed, significant evidence that supports the use of an old neuroleptic compound, thioridazine (TZ), for the management of MDR-TB and XDR-TB infections and which has been shown to inhibit efflux pumps of bacteria. The argument has been previously presented but no one seems to be listening - and the disease continues unabated when there is a very good probability that the suggested drug will prove to be effective. When the prognosis is poor, available therapy predictably ineffective and death is inevitable, compassionate therapy with TZ should be contemplated. The risks are small and the rewards great.
Export Options
About this article
Cite this article as:
Amaral L., Martins M., Viveiros M., Molnar J. and Kristiansen E. J., Promising Therapy of XDR-TB/MDR-TB with Thioridazine an Inhibitor of Bacterial Efflux Pumps, Current Drug Targets 2008; 9 (9) . https://dx.doi.org/10.2174/138945008785747798
DOI https://dx.doi.org/10.2174/138945008785747798 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial (Thematic Issue: Recent Advances in the Structure-Based Drug Design and Discovery)
Current Topics in Medicinal Chemistry Pharmacological Activity of Natural Non-glycosylated Triterpenes
Mini-Reviews in Organic Chemistry Acylhydrazide Schiff Bases: DPPH Radical and Superoxide Anion Scavengers
Medicinal Chemistry Biochemical Aspects of Nitric Oxide
Current Pharmaceutical Design Understanding the Molecular Mechanisms of Rifaximin in the Treatment of Gastrointestinal Disorders – A Focus on the Modulation of Host Tissue Function
Mini-Reviews in Medicinal Chemistry Novel Drug Delivery Magnetite Nano-systems Used in Antimicrobial Therapy
Current Organic Chemistry Anti-TNF and Pouch Surgery for Ulcerative Colitis: The Ones who Blame for More Complications?
Current Drug Targets New Vaccines and Delivery Strategies for Adult Immunization
Current Immunology Reviews (Discontinued) Withdrawal Notice: Drug Repurposing for Prospective Anti-Cancer Agents Along with the Clinical Status of the Repurposed Drug
Anti-Cancer Agents in Medicinal Chemistry Guanidinyl and Amide Conjugated Benzothiazoles as Potential Anti- Tubercular Agent and their Cytotoxicity Study
Anti-Infective Agents Nano-Based Anti-Tubercular Drug Delivery and Therapeutic Interventions in Tuberculosis
Current Drug Targets Principles and Practices of Pathway Modelling
Current Bioinformatics Advancement in Microbial Cheminformatics
Current Topics in Medicinal Chemistry HIV-1 Infection In Children: A Clinical and Immunologic Overview
Current HIV Research Therapeutic and Protective Potential of Mesenchymal Stem Cells, Pharmaceutical Agents and Current Vaccines Against COVID-19
Current Stem Cell Research & Therapy Brucella Carbonic Anhydrases: New Targets for Designing Anti-Infective Agents
Current Pharmaceutical Design New Potential Biologically Active Compounds: Synthesis and Characterization of Urea and Thiourea Derivativpes Bearing 1,2,4-oxadiazole Ring
Current Organic Synthesis Surreptitious TB Infections with Recently Identified DM People: A Cross- Sectional Study
Infectious Disorders - Drug Targets Quality-by-design Enabled Chitosan Nanoparticles for Antitubercular Therapy: Formulation, Statistical Optimization, and <i>In Vitro</i> Characterization
Current Drug Therapy Synthesis, p38 Kinase Inhibitory and Anti-inflammatory Activity of New Substituted Benzimidazole Derivatives
Medicinal Chemistry